

FILE 'REGISTRY' ENTERED AT 12:52:54 ON 29 DEC 2009

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 1 S L1 FAM FULL

FILE 'HCAPLUS' ENTERED AT 12:53:33 ON 29 DEC 2009

L4 7 S L3

=> file reg  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:52:54 ON 29 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2009 HIGHEST RN 1198837-82-9  
DICTIONARY FILE UPDATES: 28 DEC 2009 HIGHEST RN 1198837-82-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10529431claim17.str



chain nodes :  
21 22 23 29 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52  
  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 24 25 26  
27 28 30 31 32 33 34 35  
  
chain bonds :  
2-21 8-47 9-46 10-45 11-38 12-40 13-15 16-39 17-41 18-42 19-43 20-44  
21-22 21-23 23-24 25-48 27-49 28-29 29-30 31-50 32-51 33-36 34-37 35-52

```

ring bonds :
1-2 1-7 2-3 3-4 3-8 4-5 4-11 5-6 6-7 6-12 7-14 8-9 9-10 10-11 12-13
13-14 15-16 15-20 16-17 17-18 18-19 19-20 24-25 24-28 25-26 26-27 27-28
30-31 30-35
31-32 32-33 33-34 34-35
exact/norm bonds :
1-2 1-7 2-3 2-21 4-5 5-6 6-7 6-12 7-14 12-13 13-14 21-22 24-25 24-28
25-26 26-27 27-28
exact bonds :
8-47 9-46 10-45 11-38 12-40 13-15 16-39 17-41 18-42 19-43 20-44 21-23
23-24 25-48 27-49 28-29 29-30 31-50 32-51 33-36 34-37 35-52
normalized bonds :
3-4 3-8 4-11 8-9 9-10 10-11 15-16 15-20 16-17 17-18 18-19 19-20 30-31
30-35 31-32 32-33 33-34 34-35

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS
22:CLASS 23:CLASS 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS 30:Atom
31:Atom 32:Atom
33:Atom 34:Atom 35:Atom 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS
41:CLASS 42:CLASS
43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS
51:CLASS 52:CLASS

```

L1 STRUCTURE UPLOADED

```

=> s l1
SAMPLE SEARCH INITIATED 12:53:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

```

```

100.0% PROCESSED 2 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 1 TO 80

```

L2 1 SEA SSS SAM L1

```

=> d l1 scan
L1 HAS NO ANSWERS


```

=> d l2 scan

```

L2 1 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzonitrile, 4-[[5-[2-[2-(2-bromophenyl)-6-fluoro-5H-imidazo[2,1-
c][1,4]benzodiazepin-10(11H)-yl]-2-oxoethyl]-1H-imidazol-1-yl]methyl]-2-
methoxy-
MF C31 H24 Br F N6 O2

```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 fam full

FULL SEARCH INITIATED 12:53:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

L3 1 SEA FAM FUL L1

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

73.33

73.55

FILE 'HCAPLUS' ENTERED AT 12:53:33 ON 29 DEC 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Dec 2009 VOL 152 ISS 1

FILE LAST UPDATED: 28 Dec 2009 (20091228/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3


L4 7 L3

=> d l4 1-7 ti abs bib

L4 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.

GI



AB Title comps. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, bond, etc.; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, etc.; R3 = H, (substituted) alkyl, alkenyl, etc.; R4, R5 = H, (substituted) alkyl, cycloalkyl, etc.; R6 = H, (substituted) alkyl, alkenyl, etc.; R7 = H, :O, :S, (substituted) alkyl, etc.; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

AN 2008:490553 HCAPLUS <<LOGINID:20091229>>

DN 148:449668

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.

IN Gordon, Thomas D.; Morgan, Barry A.

PA Societe de Conseils de Recherches et d'Applications Scientifiques, S.a.S., Fr.

SO U.S., 34pp., Cont.-in-part of U.S. Ser. No. 224428.

CODEN: USXXAM

DT Patent

LA English


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 7361656	B2	20080422	US 2006-353518	20060214

US 20060142275	A1	20060629		
WO 2000039130	A2	20000706	WO 1999-US31302	19991230
WO 2000039130	A3	20001102		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1382607	A2	20040121	EP 2003-78315	19991230
EP 1382607	A3	20040630		
EP 1382607	B1	20090819		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 7084135	B1	20060801	US 2001-868356	20010810
US 20080176835	A1	20080724	US 2007-929118	20071030
PRAI US 1998-114301P	P	19981231		
US 1998-224428	B2	19981231		
WO 1999-US31302	W	19991230		
US 2001-868356	A1	20010810		
EP 1999-968984	A3	19991230		
US 2006-353518	A3	20060214		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OS MARPAT 148:449668  
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2009 ACS on STN  
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors  
GI



AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over

Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine.  
This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.  
Pharmaceutical composition comprising the compound I and methods of treating cancer and other diseases are disclosed.

AN 2006:759518 HCAPLUS <<LOGINID::20091229>>  
DN 145:188920

TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors

IN Gordon, Thomas D.; Morgan, Barry A.

PA Societe De Conseils De Recherches Et D'Applications Scientifiques, Sas, Fr.

SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 224,428, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7084135	B1	20060801	US 2001-868356	20010810
	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1382607	A2	20040121	EP 2003-78315	19991230
	EP 1382607	A3	20040630		
	EP 1382607	B1	20090819		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 7361656	B2	20080422	US 2006-353518	20060214
	US 20060142275	A1	20060629		
	US 20080176835	A1	20080724	US 2007-929118	20071030
FRAI	US 1998-114301P	P	19981231		
	US 1998-224428	B2	19981231		
	WO 1999-US31302	W	19991230		
	EP 1999-968984	A3	19991230		
	US 2001-868356	A1	20010810		
	US 2006-353518	A3	20060214		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 145:188920


RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2009 ACS ON STN

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

GI



AB Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor (FTI) and one or more of an anthracycline. An example FTI is I. Examples were given for assessment of farnesyl transferase inhibition in intact cells and cleavage of TRAF1 in C15 cells treated with a FTI and doxorubicin combination.

AN 2004:291952 HCAPLUS <<LOGINID::20091229>>

DN 140:315043

TI Compositions containing farnesyl transferase inhibitors for the treatment of nasopharyngeal carcinoma

IN Prevost, Gregoire; Busson, Pierre; Vicat, Jean-Michel

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S., Fr.; Centre National De Recherche Scientifique

SO PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028541	A2	20040408	WO 2003-IB4922	20030929
WO 2004028541	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003274565	A1	20040419	AU 2003-274565	20030929
EP 1542691	A2	20050622	EP 2003-758540	20030929
EP 1542691	B1	20090107		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006500421	T	20060105	JP 2004-539385	20030929
AT 419852	T	20090115	AT 2003-758540	20030929
ES 2316811	T3	20090416	ES 2003-758540	20030929
US 20060166907	A1	20060727	US 2005-529431	20050325
US 20080161253	A1	20080703	US 2008-74729	20080306
PRAI US 2002-414103P	P	20020927		
WO 2003-IB4922	W	20030929		
US 2005-529431	A1	20050325		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 140:315043

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)



RE.CNT 3        THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
                 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4    ANSWER 4 OF 7    HCAPLUS    COPYRIGHT 2009 ACS on STN

TI    Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive  
      nasopharyngeal carcinoma cells treated with doxorubicin combined with a  
      farnesyl-transferase inhibitor

AB    Epstein-Barr virus (EBV)-associated nasopharyngeal carcinomas (NPC) are much  
      more sensitive to chemotherapy than other head and neck carcinomas.  
      Spectacular regressions are frequently observed after induction chemotherapy.  
      However, these favorable responses are difficult to predict and often of  
      short duration. So far there have been only few expts. to investigate the  
      mechanisms which underline the cytotoxic effects of anti-neoplastic drugs  
      against NPC cells. In addition, these studies were performed almost entirely  
      on EBV-neg. cell lines therefore not truly representative of NPC cells.  
      For the first time, we have used two EBV-pos. NPC tumor lines derived from  
      a North African (C15) and a Chinese (C666-1) patient as in vitro targets  
      for a panel of anti-neoplastic agents. Doxorubicin, taxol and in a lesser  
      extent cis-platinum efficiently inhibited NPC cell proliferation at clin.  
      relevant concns., but all three agents failed to induce apoptosis.  
      However, massive apoptosis of C15 cells was achieved when doxorubicin (1  
      µM) was combined with a farnesyl-transferase inhibitor, BIM 2001 (5  
      µM). Moreover, this apoptotic process was associated with a  
      caspase-dependent early cleavage of the TNF-receptor associated factor 1  
      (TRAF-1) mol., a signaling adaptor which is specifically expressed in  
      latently EBV-infected cells. TRAF-1 cleavage might become a useful  
      indicator of chemo-induced apoptosis in EBV-associated NPCs.

AN    2003:28618    HCAPLUS <<LOGINID::20091229>>  
DN    139:46523

TI    Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive  
      nasopharyngeal carcinoma cells treated with doxorubicin combined with a  
      farnesyl-transferase inhibitor

AU    Vicat, Jean-Michel; Ardila-Orsorio, Hector; Khabir, Abdelmajid; Brezak,  
      Marie-Christine; Viossat, Isabelle; Kasprzyk, Philip; Jliidi, Rachid;  
      Opolon, Paule; Ooka, Tadamassa; Prevost, Gregoire; Huang, Dolly P.;  
      Busson, Pierre

CS    UMR 1598, Institut Gustave Roussy, Villejuif, 94805, Fr.

SO    Biochemical Pharmacology (2003), 65(3), 423-433

      CODEN: BCPCA6; ISSN: 0006-2952

PB    Elsevier Science Inc.

DT    Journal

LA    English

OSC.G 6        THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 47       THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD  
                 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4    ANSWER 5 OF 7    HCAPLUS    COPYRIGHT 2009 ACS on STN

TI    Preparation of pharmaceutical compositions containing mikanolide,  
      dihydromikanolide or an analog thereof combined with another anticancer  
      agent for therapeutic use in cancer treatment

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB    The invention concerns a product comprising at least mikanolide (I),  
      dihydromikanolide or an analog, e.g., II [R1 = H, SR4, NR4R5; R2 = SR6,  
      NR6R7; R3 = OH, O-acyl, O-silyl, O-carbamyl; R4, R6 = alkyl, cycloalkyl,  
      (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R5, R7 =

H, alkyl, cycloalkyl, (cycloalkyl)alkyl, hydroxyalkyl, (un)substituted aryl, aralkyl; R4R5 = 5- to 7-membered N-containing ring] and III, or their pharmaceutically acceptable salts, combined with at least one other anticancer agent for simultaneous, sep. or prolonged therapeutic use in cancer treatment. In a preferred embodiment of the invention, the mikanolide, dihydromikanolide or one analog thereof is combined with enzymic inhibitors such as G heterotrimeric protein inhibitors, IV [X = R22; Y = R18; XY = 6-membered ring, CHR18CHR19; R11 = H, lower alkyl, alkylthio; R12, R13 = H, lower alkyl; R14 = O, H2; R5 = H, lower alkyl, (cycloalkyl)alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R16, R17 = H, CONHCHR13CO2R14, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18R19 = aryl or heterocyclyl ring; R20, R21 = H, aryl, heterocyclyl, alkyl, arylalkyl, heterocyclylalkyl; R22 = NR9, S, O; R23 = ; R24 = H, lower alkyl], V (R18, R19 = H, lower alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R18R19 = aryl or heterocyclyl ring) or VI (R22 = NR9, S, O), or alkylating agents such as cis-platin. Thus, VII was prepared from mikanolide. VII was tested for cell proliferation inhibition activity [only 34% of cells lived when combined with VIII·HCl (vs. human colon cancer HT-29 cells)].

AN 2002:927175 HCAPLUS <<LOGINID:20091229>>  
 DN 138:14131  
 TI Preparation of pharmaceutical compositions containing mikanolide, dihydromikanolide or an analog thereof combined with another anticancer agent for therapeutic use in cancer treatment  
 IN Prevost, Gregoire; Coulomb, Helene; Lavergne, Olivier; Lanco, Christophe; Teng, Beng-Poon  
 PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.  
 SO PCT Int. Appl., 103 pp.  
 CODEN: P1XXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096348	A2	20021205	WO 2002-FR1800	20020529
	WO 2002096348	A3	20040506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	FR 2825278	A1	20021206	FR 2001-7104	20010530
	CA 2448528	A1	20021205	CA 2002-2448528	20020529
	AU 2002313087	A1	20021209	AU 2002-313087	20020529
	EP 1438039	A2	20040721	EP 2002-738284	20020529
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004533456	T	20041104	JP 2002-592861	20020529
	CN 1691941	A	20051102	CN 2002-812592	20020529
	HU 2004000153	A2	20070730	HU 2004-153	20020529
	US 20040138245	A1	20040715	US 2003-478387	20031211
FR	FR 2001-7104	A	20010530		
	WO 2002-FR1800	W	20020529		
OS	MARPAT 138:14131				

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2009 ACS ON STN  
 TI Product inhibiting heterotrimeric G protein signal transduction combined  
 with another anticancer agent for therapeutic use in cancer treatment  
 AB The invention provides a product inhibiting heterotrimeric G protein  
 signal transduction combined with another anticancer agent, in particular  
 a farnesyltransferase inhibitor, taxol or gemcitabine, for simultaneous,  
 sep., or prolonged therapeutic use in cancer treatment.  
 AN 2001:359845 HCAPLUS <<LOGINID:20091229>>  
 DN 134:361346  
 TI Product inhibiting heterotrimeric G protein signal transduction combined  
 with another anticancer agent for therapeutic use in cancer treatment  
 IN Prevost, Gregoire; Lonchamps, Marie-Odile; Gordon, Thomas; Morgan, Barry  
 PA Societe de Conseils de Recherches et d'Applications Scientifiques  
 (S.C.R.A.S.), Fr.  
 SO PCT Int. Appl., 42 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001034203	A1	20010517	WO 2000-FR3098	20001108
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2800616	A1	20010511	FR 1999-14037	19991109
	FR 2800616	B1	20020118		
	FR 2803524	A1	20010713	FR 2000-104	20000106
	FR 2803524	B1	20020419		
	CA 2390317	A1	20010517	CA 2000-2390317	20001108
	EP 1233787	A1	20020828	EP 2000-976116	20001108
	EP 1233787	B1	20041208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 2002003241	A2	20030228	HU 2002-3241	20001108
	HU 2002003241	A3	20060728		
	JP 2003513940	T	20030415	JP 2001-536200	20001108
	EP 1430934	A1	20040623	EP 2004-75491	20001108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	AT 284224	T	20041215	AT 2000-976116	20001108
	PT 1233787	E	20050429	PT 2000-976116	20001108
	ES 2234692	T3	20050701	ES 2000-976116	20001108
	RU 2298417	C2	20070510	RU 2002-115262	20001108
	US 7034024	B1	20060425	US 2002-129569	20020621
	US 20060074078	A1	20060406	US 2005-272304	20051110
	US 20090270341	A1	20091029	US 2008-496896	20090702
PRAI	FR 1999-14037	A	19991109		
	FR 2000-104	A	20000106		
	EP 2000-976116	A3	20001108		
	WO 2000-FR3098	W	20001108		


US 2002-129569 A3 20020621  
US 2005-272304 B3 20051110

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OS MARPAT 134:361346

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2009 ACS ON STN  
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related  
compounds as prenyl transferase inhibitors.

GI



AB Title compds. [I; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

AN 2000:457071 HCAPLUS <<LOGINID:20091229>>  
DN 133:89553  
TI Preparation of imidazopyrazines, imidazobenzodiazepines, and related  
compounds as prenyl transferase inhibitors.  
IN Gordon, Thomas B.; Morgan, Barry A.  
PA Societe de Conseils de Recherches et d'Applications Scientifiques S.A.,  
Fr.

SO PCT Int. Appl., 95 pp.  
CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039130	A2	20000706	WO 1999-US31302	19991230
	WO 2000039130	A3	20001102		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2356756 A1 20000706 CA 1999-2356756 19991230  
 EP 1140942 A2 20011010 EP 1999-968984 19991230  
 EP 1140942 B1 20040310

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

HU 2001004708 A2 20020429 HU 2001-4708 19991230  
 HU 2001004708 A3 20040528  
 EP 1382607 A2 20040121 EP 2003-78315 19991230  
 EP 1382607 A3 20040630  
 EP 1382607 B1 20090819

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI, CY

AT 261447 T 20040315 AT 1999-968984 19991230  
 PT 1140942 E 20040531 PT 1999-968984 19991230  
 ES 2215420 T3 20041001 ES 1999-968984 19991230  
 RU 2241712 C2 20041210 RU 2001-121317 19991230  
 AT 440100 T 20090915 AT 2003-78315 19991230  
 ES 2328564 T3 20091116 ES 2003-78315 19991230  
 NO 2001003281 A 20010829 NO 2001-3281 20010629  
 NO 321057 B1 20060306

US 7084135 B1 20060801 US 2001-868356 20010810  
 US 7361656 B2 20080422 US 2006-353518 20060214  
 US 20060142275 A1 20060629  
 US 20080176835 A1 20080724 US 2007-929118 20071030

FRAI US 1998-114301P P 19981231  
 US 1998-224428 A1 19981231  
 EP 1999-968984 A3 19991230  
 WO 1999-US31302 W 19991230  
 US 2001-868356 A1 20010810  
 US 2006-353518 A3 20060214

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 133:89553

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT